Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

BACKGROUND: Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robert H, Casbard, Angela, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew, Howell, Sacha J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052734/
https://www.ncbi.nlm.nih.gov/pubmed/32035020
http://dx.doi.org/10.1016/S1470-2045(19)30817-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052734/
https://www.ncbi.nlm.nih.gov/pubmed/32035020
http://dx.doi.org/10.1016/S1470-2045(19)30817-4

Ejemplares similares